A Phase II Trial of Cabozantinib With Patients With Refractory GCTs

StatusCompleted
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 4 more changesShow less
    • Primary completion date changed from estimate of Jan 2027 to Jul 31, 2026
    • Eligibility criteria expanded, about 31 words
    • Secondary endpoints: details revised at 1 of 4 entries
    • Site details revised
  2. Primary completion date: Jan 2026 to Jan 2027
    • Secondary endpoints: details revised at 2 of 4 entries
    v17
  3. Primary completion date: Aug 2025 to Jan 2026
    • Study completion date: Aug 2026 to Jan 2027
    v16
  4. Collaborators: 1 to 2v15
  5. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date: Feb 2025 to Aug 2025
    • Study completion date: Feb 2026 to Aug 2026
    • Site details revised
    v14
Show 12 earlier versionsHide 12 earlier versions
  1. Primary completion date: Dec 2024 to Feb 2025
    • Study completion date: Dec 2025 to Feb 2026
    • Site contact updated
    v13
  2. Re-verified, no change to tracked fieldsv12
  3. Trial status: Suspended to Recruiting
    • Site details revised
    v11
  4. Trial status: Recruiting to Suspended Sponsor's reason: pending ICF updates
    • Site details revised
    v10
  5. Lead sponsor: Nabil Adra to Jennifer King
    • Site contact updated
    v9
  6. Start date: May 28, 2021 to Jun 10, 2021v8
  7. Eligibility criteria expanded, about 489 wordsv7
  8. Eligibility criteria shortened, about 495 wordsv6
  9. Enrollment target: 25 to 50v5
  10. Re-verified, no change to tracked fieldsv4
  11. Eligibility criteria expanded, about 4 wordsv3
  12. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 2021 to May 28, 2021
    • Site details revised
    • Study title shortened, about 3 words
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of the CTO-IUSCCC-0752 study is to investigate the use of Cabozantinib for patients with incurable, refractory germ cell tumors. Patients will be treated until evidence of disease progression, non-compliance with study protocol, unacceptable major toxicity, at subject's own request for withdrawal, or if the study closes for any reason.
Trial Details
NCT Number NCT04876456
Lead Sponsor Jennifer King
Collaborators: Exelixis, JDS Foundation Testis Cancer Clinical Trials Support Fund
Conditions
(from sponsor)		 Germ Cell Tumor, Seminoma, Non-seminomatous Germ Cell Tumor, Ovarian Germ Cell Tumor
Related terms Neoplasms, Germ Cell and Embryonal, Nonseminomatous germ cell tumor, Seminoma
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov